The GINA guidelines (GL)1, the BTS-SIGN GL2, and the paediatric PRACTALL GL3, indicate inhaled corticosteroids (ICS) as the frst choice for controller therapy of paediatric asthma. The authors of BTS-SIGN GL recommended a leukotriene receptor antagonist, if ICS cannot be administered. Montelukast (MLK) is the most commonly used in children. If ICS remain the frst choice, they can be considered the Gold Standard for pharmacological asthma prevention and the value of any alternative treatment must be measured against them, not only against a placebo. Here we will try to shed some light as to which of those two drugs is better according to the present evidence.
|Number of pages||5|
|Journal||Allergologia et Immunopathologia|
|Publication status||Published - 2009|